Results 181 to 190 of about 7,937 (220)

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy. [PDF]

Heart Fail Rev
Ang SP, Chia JE, Mukherjee D.
europepmc   +1 more source

Research Status in Transthyretin Amyloid Cardiomyopathy

Advances in Clinical Medicine
openaire   +1 more source

Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy

JACC: CardioOncology
openaire   +1 more source

Correction to: Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. [PDF]

Eur Heart J
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Transthyretin amyloid cardiomyopathy

Medicina Clínica (English Edition), 2021
Transthyretin (TTR) cardiac amyloidosis is a severe, progressive, infiltrative disease caused by the deposition of TTR at cardiac level. It may be due to a genetic alteration in its hereditary form (ATTRv) or as a consequence of an age-related degenerative process (ATTRwt). Thanks to advances in imaging techniques and the possibility of achieving a non-
Pablo, Garcia-Pavia, Fernando, Domínguez, Esther, Gonzalez-Lopez   +2 more
openaire   +4 more sources

Transthyretin amyloid cardiomyopathy

The American Journal of the Medical Sciences, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed cause of heart failure and arrhythmia. This differential diagnosis should particularly be considered in older patients with left ventricular hypertrophy (LVH) who are also suffering from heart failure with preserved ejection fraction (HFpEF) or aortic valve stenosis.
Giuseppe, Famularo, Guido, Ventroni
openaire   +4 more sources

Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy

American Journal of Therapeutics, 2021
Background: Deposition of wild-type or mutant transthyretin (TTR) amyloid fibrils in the myocardium causes TTR amyloid cardiomyopathy (ATTR-CM). Targeted therapeutics for ATTR-CM include TTR stabilizers (tafamidis and diflunisal) and oligonucleotide drugs (revusiran, patisiran, and inotersen).
Courtney M, Campbell, Cyril Ayuk Mbeng Takem, Baiyee, Salem, Almaani, Naresh, Bumma, Nidhi, Sharma, Samantha, LoRusso, Elyse, Redder, Jordan, Bittengle, Katherine, Pfund, Miriam, Friemer, Matthew, Tong, Rami, Kahwash, Yvonne, Efebera, Samir, Parikh, Ajay, Vallakati   +14 more
openaire   +2 more sources

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy [PDF]

New England Journal of Medicine, 2018
Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in the myocardium. The deposition occurs when wild-type or variant transthyretin becomes unstable and misfolds. Tafamidis binds to transthyretin, preventing tetramer dissociation and amyloidogenesis.In a multicenter, international, double-blind, placebo ...
Mathew S Maurer, Perry M Elliott, Giampaolo Merlini   +2 more
exaly   +5 more sources

Transthyretin Amyloid Cardiomyopathy—Current and Future Therapies

Annals of Pharmacotherapy, 2021
Objective: To describe the clinical presentation of transthyretin amyloid cardiomyopathy (ATTR-CM) and discuss current treatments and investigational products and their effect on patient outcomes. Data Sources: A literature search was performed in PubMed (September 2018 to December 2020) using the following keywords: transthyretin amyloidosis ...
Jankhna D. Yadav, Harjot Othee, Kelly A. Chan, Damen C. Man, Paul P. Belliveau, Jennifer Towle   +5 more
openaire   +2 more sources

Tafamidis for Transthyretin Amyloid Cardiomyopathy

New England Journal of Medicine, 2019
Abstract not ...
Maurer, Mathew S, Sultan, Marla B, Rapezzi, Claudio   +2 more
openaire   +4 more sources